Compass Therapeutics
CMPX
108 hedge funds and large institutions have $206M invested in Compass Therapeutics in 2025 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 29 reducing their positions, and 10 closing their positions.
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
40% more capital invested
Capital invested by funds: $147M → $206M (+$59.1M)
17% more funds holding
Funds holding: 92 → 108 (+16)
4.76% more ownership
Funds ownership: 73.68% → 78.44% (+4.8%)
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
30% less call options, than puts
Call options by funds: $4.52M | Put options by funds: $6.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$13.7M |
| 2 |
JP Morgan Chase
New York
|
+$5.09M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$2.33M |
| 4 |
SG Americas Securities
New York
|
+$1.45M |
| 5 |
Millennium Management
New York
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$5.37M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$2.69M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.17M |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
-$450K |
| 5 |
Goldman Sachs
New York
|
-$417K |
CMPX Hedge Fund Activity: Q1 2025 in Review
108 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q1 2025, worth a combined $206M — up 40% from $147M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CMPX positions and 10 closed out — a net gain of 16 holders — while 30 added to existing stakes and 29 trimmed.
The largest buyer was Tang Capital Management, adding an estimated $13.7M. The largest seller was Adage Capital Partners, cutting an estimated $5.37M.
- 108 institutional investors held Compass Therapeutics (CMPX) as of Q1 2025, up from 92 in Q4 2024.
- Funds reported $206M of Compass Therapeutics stock for Q1 2025, up 40% quarter-over-quarter.
- 26 funds opened new Compass Therapeutics positions in Q1 2025 and 10 closed out, a net change of +16 holders.
- The largest Compass Therapeutics buyer in Q1 2025 was Tang Capital Management, an estimated $13.7M added.
- The largest Compass Therapeutics seller in Q1 2025 was Adage Capital Partners, an estimated $5.37M sold.
Based on aggregated 13F filings for Q1 2025.